ClinicalTrials.gg
SuspendedNCT03180450Updated Nov 18, 2026

The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-HF)

A Phase 1/2 interventional study of Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) and conventional treatment in Heart Failure, sponsored by Sclnow Biotechnology Co., Ltd.. Suspended at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Sclnow Biotechnology Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was suspended
Others
Updated Nov 18, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
180th of 247
60 · median 130
Started
2026
with 42 others
Phase 1/2
14 of 377
7 open now
Registered
90th of 377
by date

Among the 377 studies in Heart Failure with a site in China, this one is the 180th largest by planned enrollment of the 247 interventional ones that give a count, is one of 43 that started in 2026, is one of 14 in phase 1/2, and was the 90th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

The purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating heart failure patients

Read the detailed description

This is a randomized, paralleled study. Patients will be divided into two groups of treatment and control. all of them will receive conventional treatment based on specific condition, including digitalis, milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), and antiplatelet aggregation etc. Treatment group patients will receive hUC-MSC. Follow-up visit will occur on 3 months, 6 months, and 12 months after the cell transfusion. Vital signs, blood routine test, urine routine test, liver function examination, etc, will be placed to evaluate the safety of hUC-MSC treatment. And the change of symptoms to evaluate the efficacy.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure
  • Human Umbilical Cord Mesenchymal Stem Cells
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • volunteer to participate in clinical trial, and sign form
  • with cardiac failure symptoms, including oppression in chest, breathe hard, lower limb edema. And class as two to four
  • heart color ultrasound indicate (LVEF) \< 40%
  • content of serum NT-proBNP > 450pg/ml

Exclusion criteria

Exclusion Criteria:

  • with severe drug allergy history or allergic constitution
  • patients were severe infected
  • with malignant tumor or with high tumor marker
  • with severe cardiorespiratory dysfunction, hematological system disease
  • with severe mental disorder, cognitive impairment
  • with persistent atrial fibrillation, valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy or restrictive cardiomyopathy patients
  • end-stage renal insufficiency, pregnancy, or breast feeding women
  • bleeding tendency, active gastrointestinal ulcer
  • recent have major surgery, stroke, cancer, hepatic function insufficiency or other life-threatening condition.
  • under other therapy that possibly influence MSC security or efficacy
  • donor: , active /C infection, Syphilitic antibody positive
  • participant/donor: alcoholism, drug addicted, mental disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment group

    conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.

    Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) · Drug: conventional treatment

  • Placebo comparator
    Control group

    Conventional treatment

    Drug: conventional treatment

Interventions

  • BiologicalAllogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)

    Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.

  • Drugconventional treatment

    The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.

06

What researchers measure

Primary outcomes

  1. Heart color ultrasound evaluation

    Criteria: * Excellent: ejection fraction improve to \> 50%; * Efficient: ejection fraction improved; * Inefficient: ejection fraction same as before treatment; * Exacerbation: ejection fraction declined.

    Time frame: 12 months

Secondary outcomes

  1. Single therapy effectiveness evaluation

    Evaluate criteria: * Recovery: symptoms disappear * Excellent: symptoms improved obviously * Efficient: symptoms improved * Inefficient: symptoms no change or worse

    Time frame: 12 months

07

Study locations

1 site
  • Inner Mongolia International Mongolian Hospital
    Hohhot, Inner Mongolia 010065, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Jun 2027, 5 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Dec 2025 → Dec 2026, primary completion Jun 2026 → Jun 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2017
First posted
Jun 8, 2017
StartEst.
Dec 31, 2026was Dec 2025
Primary completionEst.
Jun 30, 2027was Jun 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 31, 2025→Dec 31, 2026
Nov 18, 2026
Primary completion
Jun 30, 2026→Jun 30, 2027
Nov 18, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Dec 31, 2025→Dec 31, 2026
    Primary completion Jun 30, 2026→Jun 30, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03180450
Lead sponsor
Sclnow Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 8, 2017
Start date
Dec 31, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Nashundalai
study director · Inner Mongolia International Mongolian Hospital
Lei Guo, Dr.
study chair · China-Japan Union Hospital, Jilin University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion